The Role of Genetic and Epigenetic Regulation in Intestinal Fibrosis in Inflammatory Bowel Disease: A Descending Process or a Programmed Consequence? DOI Open Access
Sara Jarmakiewicz-Czaja, Aneta Sokal, Katarzyna Ferenc

et al.

Genes, Journal Year: 2023, Volume and Issue: 14(6), P. 1167 - 1167

Published: May 27, 2023

Inflammatory bowel diseases (IBDs) are a group of chronic characterized by recurring periods exacerbation and remission. Fibrosis the intestine is one most common complications IBD. Based on current analyses, it evident that genetic factors mechanisms, as well epigenetic factors, play role in induction progression intestinal fibrosis Key mechanisms appear to be significant include NOD2, TGF-β, TLRs, Il23R, ATG16L1. Deoxyribonucleic acid (DNA) methylation, histone modification, ribonucleic (RNA) interference primary mechanisms. Genetic which seem important pathophysiology IBD, may potentially used targeted therapy future. Therefore, aim this study was gather discuss selected factors.

Language: Английский

Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies DOI
Giacomo Cozzi, Laura Scagnellato, Mariagrazia Lorenzin

et al.

Nature Reviews Rheumatology, Journal Year: 2023, Volume and Issue: 19(8), P. 503 - 518

Published: June 29, 2023

Language: Английский

Citations

23
Diagnosis and management of inflammatory bowel disease DOI
Lili Li, Rui Cheng,

Yushan Wu

et al.

Journal of Evidence-Based Medicine, Journal Year: 2024, Volume and Issue: 17(2), P. 409 - 433

Published: June 1, 2024

Abstract Inflammatory bowel disease (IBD) is a chronic and relapsing immune‐mediated of the gastrointestinal tract with gradually increasing global incidence prevalence. A prolonged course IBD leads to decline in patient quality life creation substantial economic burden on society. Owing lack specific diagnostic markers, diagnosis still needs gold standard based combination clinical manifestations, imaging, laboratory, endoscopic results. Accordingly, current goals treatment are alleviate symptoms reduce recurrence rates. Therefore, it imperative develop set procedures diagnose treat IBD. In this review, we summarize prominent emerging studies, outline classical contemporary approaches diagnosing managing IBD, integrate multiple guidelines. Furthermore, propose possibility establishing an early comprehensive workflow personalized management strategy future. We aim enhance standardization for

Language: Английский

Citations

14
Inflammatory Bowel Disease: A Comprehensive Analysis of Molecular Bases, Predictive Biomarkers, Diagnostic Methods, and Therapeutic Options DOI Open Access
Eguzkiñe Díez-Martín, Leidi Hernández-Suárez, Carmen Muñoz‐Villafranca

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7062 - 7062

Published: June 27, 2024

In inflammatory bowel diseases (IBDs), such as Crohn's disease (CD) and ulcerative colitis (UC), the immune system relentlessly attacks intestinal cells, causing recurrent tissue damage over lifetime of patients. The etiology IBD is complex multifactorial, involving environmental, microbiota, genetic, immunological factors that alter molecular basis organism. Among these, microbiota cells play pivotal roles; generates antigens recognized by antibodies, while autoantibodies target attack membrane, exacerbating inflammation damage. Given altered framework, analysis multiple biomarkers in patients proves exceedingly valuable for diagnosing prognosing IBD, including markers like C reactive protein fecal calprotectin. Upon detection classification patients, specific treatments are administered, ranging from conventional drugs to new biological therapies, antibodies neutralize molecules tumor necrosis factor (TNF) integrin. This review delves into targets, biomarkers, treatment options, monitoring techniques, and, ultimately, current challenges management.

Language: Английский

Citations

13
Molecular Foundations of Inflammatory Diseases: Insights into Inflammation and Inflammasomes DOI Creative Commons

Mi Eun Kim,

Jun Sik Lee

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(1), P. 469 - 484

Published: Jan. 3, 2024

Inflammatory diseases are a global health problem affecting millions of people with wide range conditions. These diseases, including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), osteoarthritis (OA), gout, and diabetes, impose significant burden on patients healthcare systems. A complicated interaction between genetic variables, environmental stimuli, dysregulated immune responses shows the complex biological foundation various diseases. This review focuses molecular mechanisms underlying function inflammasomes inflammation. We investigate impact factors progression explore connection inflammation inflammasome activation, examine incidence in relation to inflammasomes.

Language: Английский

Citations

9
Fibrosis: cross-organ biology and pathways to development of innovative drugs DOI
Florian Rieder, Laura E. Nagy, Toby M. Maher

et al.

Nature Reviews Drug Discovery, Journal Year: 2025, Volume and Issue: unknown

Published: March 18, 2025

Language: Английский

Citations

1
Adenosine in Intestinal Epithelial Barrier Function DOI Creative Commons
Mariya Stepanova, Carol M. Aherne

Cells, Journal Year: 2024, Volume and Issue: 13(5), P. 381 - 381

Published: Feb. 23, 2024

At the intestinal front, several lines of defense are in place to resist infection and injury, mucus layer, gut microbiome strong epithelial junctions, name a few. Their collaboration creates resilient barrier. In disorders, such as inflammatory bowel disease (IBD), barrier function is compromised, which results rampant inflammation tissue injury. response destruction, epithelium releases adenosine, small but powerful nucleoside that functions an alarm signal. Amidst chaos inflammation, adenosine aims restore order. Within scope its effects ability regulate integrity. This review define contributions production, microbiome-dependent protection, tight junction dynamics, chloride secretion acid–base balance reinforce importance

Language: Английский

Citations

6
Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease DOI Open Access
Pierluigi Puca, I. Capobianco,

Gaetano Coppola

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(5), P. 2789 - 2789

Published: Feb. 28, 2024

The advent of biologic drugs has revolutionized the treatment Inflammatory Bowel Disease, increasing rates response and mucosal healing in comparison to conventional therapies by allowing corticosteroid-refractory cases reducing corticosteroid-related side effects. However, (anti-TNFα inhibitors, anti-α4β7 integrin anti-IL12/23) are still burdened that hover around 40% (in biologic-naïve patients) or lower (for biologic-experienced patients). Moreover, knowledge mechanisms underlying drug resistance loss is scarce. Several cellular molecular determinants implied therapeutic failure; genetic predispositions, form single nucleotide polymorphisms sequence cytokines Human Leukocyte Antigen, an altered expression other molecules involved inflammation cascade, play most important role. Accessory include gut microbiota dysregulation. In this narrative review current recent literature, we shed light on mentioned failure order pave way for a more personalized approach could help avoid unnecessary treatments toxicities.

Language: Английский

Citations

6
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review DOI Open Access
Javier Plaza Zamora, Alejandro Mínguez, Guillermo Bastida

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(7), P. 3717 - 3717

Published: March 27, 2024

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the digestive tract usually characterized by diarrhea, rectal bleeding, and abdominal pain. IBD includes Crohn’s ulcerative colitis as main entities. debilitating condition that can lead to life-threatening complications, involving possible malignancy surgery. The available therapies aim achieve long-term remission prevent progression. Biologics are bioengineered therapeutic drugs mainly target proteins. Although they have revolutionized treatment IBD, their potential benefits limited due large interindividual variability in clinical response terms efficacy toxicity, resulting high rates failure. It therefore important find biomarkers provide tailor-made strategies allow for patient stratification maximize minimize adverse events. Pharmacogenetics has optimize biologics selection identifying genetic variants, specifically single nucleotide polymorphisms (SNPs), which underlying factors associated with an individual’s drug response. This review analyzes current knowledge variants biological agent (infliximab, adalimumab, ustekinumab, vedolizumab) IBD. An online literature search various databases was conducted. After applying inclusion exclusion criteria, 28 reports from 1685 results were employed review. most significant SNPs potentially useful predictive linked immunity, cytokine production, immunorecognition.

Language: Английский

Citations

6
The Earlier You Find, the Better You Treat: Red Flags for Early Diagnosis of Inflammatory Bowel Disease DOI Creative Commons

Laura Cantoro,

Rita Monterubbianesi,

Giuliano Falasco

et al.

Diagnostics, Journal Year: 2023, Volume and Issue: 13(20), P. 3183 - 3183

Published: Oct. 12, 2023

Delayed diagnosis is a challenge in the management of inflammatory bowel disease (IBD). Several studies show significant association between diagnostic delay and progression to complications surgery, especially Crohn’s (CD). What risk factors are associated with IBD remains unclear. In order reduce delay, Red Flags Index has been developed validated. The combination score non-invasive biomarkers such as fecal calprotectin seems be highly accurate screening patients underlying referred for further workup eventual early effective treatment strategies. Our literature review aims obtain comprehensive overview impacts on potential IBD, how tools may reducing future perspectives this field.

Language: Английский

Citations

13
An inflammation-related subtype classification for analyzing tumor microenvironment and clinical prognosis in colorectal cancer DOI Creative Commons

Jun‐Peng Pei,

Yuye Gao,

Aiwen Wu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: April 29, 2024

Background The inflammatory response plays an essential role in the tumor microenvironment (TME) of colorectal cancer (CRC) by modulating growth, progression, and to therapy through recruitment immune cells, production cytokines, activation signaling pathways. However, molecular subtypes risk score prognostic model based on remain be further explored. Methods Inflammation-related genes were collected from signature database identified using nonnegative matrix factorization TCGA cohort. We compared clinicopathological features, infiltration, somatic mutation profile, survival prognosis, drug sensitivity between subtypes. was developed LASSO multivariate Cox regression above results independently validated GEO Moreover, we explored biological functions hub gene, receptor interacting protein kinase 2 (RIPK2), leveraging proteomics data, vivo , vitro experiments. Results two inflammation-related (inflammation-low inflammation-high) have excellent internal consistency stability. Inflammation-high subtype showed higher cell infiltration increased common chemotherapeutic drugs, while inflammation-low may more suitable for immunotherapy. Besides, differ significantly pathway enrichment functions. In addition, 11-gene constructed strong assessment power could serve as a novel marker predict CRC patients. Finally, RIPK2 crucial promoting malignant proliferation experiment. Conclusions This study provides new insights into heterogeneity opportunities treatment development clinical decision making.

Language: Английский

Citations

5